CD274 and non-small cell lung carcinoma: Preclinical and clinical studies have established the effectiveness and safety of combined PD-1/PD-L1 inhibitor and chemotherapy as the first-line therapy for advanced NSCLC, which is the preferred treatment option in clinical practice.